Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
2.205
-0.015 (-0.68%)
Sep 4, 2025, 1:55 PM - Market open
Immix Biopharma Employees
As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,101,264
Market Cap
63.58M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21 | 4 | 23.53% |
Dec 31, 2023 | 17 | 6 | 54.55% |
Dec 31, 2022 | 11 | 9 | 450.00% |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMMX News
- 10 days ago - Immix Biopharma to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Immix Biopharma Announces Other Serious Diseases Strategy - GlobeNewsWire
- 7 weeks ago - Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - GlobeNewsWire
- 2 months ago - Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 3 months ago - Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 3 months ago - Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - GlobeNewsWire